Results: There was a prostate adenocarcinoma incidence of 25.5%; all found among patients with PSA levels greater than 10ng/ml. The positive predictive value (PPV), sensitivity and specificity of DRE for prostate cancer were 0.67%, 66.7% and 88.6% with an accuracy of 82.8%; while for TRUS, the respective values were 0.58%, 58.3% and 85.7% with an accuracy of 78.7%. PSA alone had a positive predictive value of 0.16. A combination of abnormal DRE and PSA (more than 4.0ng/ml) had a positive predictive value (PPV) of 0.75 while when DRE, TRUS and PSA were all abnormal, the PPV rose to 0.80. Conclusion: A combination of DRE and PSA yields 75% diagnostic sensitivity for prostate cancer and is reliable enough to exempt TRUS where not available since it only adds 5% to this strong diagnostic combination.